ArticleDiscover oncology2025
Mendelian randomization study identifying immune cell phenotypes associated with breast cancer risk.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundGlobally, breast cancer is among the most frequent cancers, and tumor progression is greatly impacted by the immune system. Studies have revealed a correlation between the phenotypes of immune cells and the incidence of breast cancer; nevertheless, the causal relationship has yet to be fully elucidated. Hence, we sought to ascertain the causal relationship between immune cell subtypes and breast cancer through the implementation of Mendelian randomization (MR).
methodsMR analysis utilized freely available genetic data to explore the causation link between 731 immune cell phenotypes and the susceptibility to breast cancer, distinguishing between estrogen receptor-positive (ER+) and negative (ER-) subtypes. ER+ patients are sensitive to endocrine drugs, and one more way to treat with endocrine drugs than ER- patients. Inverse variance weighting (IVW), MR-Egger regression, and weighted median methods were employed to evaluate MR. The IVW analysis was used as the primary research methodology.
resultsAmong 731 immune phenotypes, we found that breast cancer was causally related to eight immune phenotypes, six of which were protective against breast cancer, while two were risk factors. After grouping breast cancers based on the ER expression, ER+ breast cancer patients were significantly causally related to seven immune phenotypes, among which three were protective against ER+ breast cancers, and four were risk factors. Furthermore, ER-breast cancer patients were significantly causally related to 10 immune phenotypes, with four being protective against ER-breast cancers and six being risk factors.
conclusionsThis MR Study proved that there is a certain genetic relationship between immune cell phenotype and breast cancer, and the related genes may have certain significance for the treatment and drug development of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.